
Customize View
Recently disclosed strategic alliances only (within the last two years)
Include Strategic Alliances for:Current subsidiaries



Strategic Alliances

Recently Disclosed Strategic Alliances
Strategic Alliance Name
Company Name
Primary Industry
Source
Agenus Inc. (NasdaqCM:AGEN)
VBI Vaccines Inc. (NasdaqCM:VBIV)
Biotechnology
VBI Vaccines Inc. (NasdaqCM:VBIV) 2023 Form 10-K
Business Description: Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFÃŸ TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Brii Biosciences Limited (SEHK:2137)
VBI Vaccines Inc. (NasdaqCM:VBIV)
Biotechnology
VBI Vaccines Inc. (NasdaqCM:VBIV) 2023 Form 10-K
Business Description: Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases primarily in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trail and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease. The company was incorporated in 2017 and is headquartered in Beijing, China.
Coalition For Epidemic Preparedness Innovations
VBI Vaccines Inc. (NasdaqCM:VBIV)
Life Sciences Tools and Services
VBI Vaccines Inc. (NasdaqCM:VBIV) 2023 Form 10-K
Business Description: Coalition For Epidemic Preparedness Innovations is a global alliance to finance and coordinate the development of new vaccines to prevent and contain infectious disease epidemics. The company carries vaccines through late preclinical studies to proof of concept and safety in humans before epidemics begin and also supports the development of vaccine platform technologies that enable rapid vaccine development. Coalition For Epidemic Preparedness Innovations enters a partnership with Affinivax, Inc. The company was incorporated in 2016 and is based in Oslo, Norway.
Glaxosmithkline Biologicals S.A.
VBI Vaccines Inc. (NasdaqCM:VBIV)
Pharmaceuticals
VBI Vaccines Inc. (NasdaqCM:VBIV) 2023 Form 10-K
Business Description: Glaxosmithkline Biologicals S.A. researches, develops, manufactures, and supplies vaccines. Its vaccination products used for traeting diseases, such as rabies, diphtheria, tetanus, yellow fever, polio, measles, mumps, rubella, and hepatitis B. GlaxoSmithKline Biologicals S.A. with was formerly known as SmithKline Beecham Biologicals S.A. The company was founded in 1945 and is based in Rixensart, Belgium. Glaxosmithkline Biologicals S.A. operates as a subsidiary of GlaxoSmithKline plc.
National Research Council Canada
VBI Vaccines Inc.
Research and Consulting Services
VBI Vaccines Inc. (NasdaqCM:VBIV) 2023 Form 10-K
Business Description: National Research Council Canada is an institution that undertake, promotes, and assists in scientific and industrial research. It offers services, such as maintaining and operating a national science library, publishing and selling scientific and technical information, working on the standardization and certification of scientific and technical apparatus and instruments and materials used, and operating and administering any astronomical observatories established or maintained by the Government of Canada. National Research Council Canada was founded in 1916 and is based in Ottawa, Canada.
National Research Council Canada
VBI Vaccines Inc. (NasdaqCM:VBIV)
Research and Consulting Services
VBI Vaccines Inc. (NasdaqCM:VBIV) 2023 Form 10-K
Business Description: National Research Council Canada is an institution that undertake, promotes, and assists in scientific and industrial research. It offers services, such as maintaining and operating a national science library, publishing and selling scientific and technical information, working on the standardization and certification of scientific and technical apparatus and instruments and materials used, and operating and administering any astronomical observatories established or maintained by the Government of Canada. National Research Council Canada was founded in 1916 and is based in Ottawa, Canada.
Strategic Innovation Fund
VBI Vaccines Inc. (NasdaqCM:VBIV)
Specialized Finance
VBI Vaccines Inc. (NasdaqCM:VBIV) 2023 Form 10-K
Business Description: There is no business description for this company.
Syneos Health, Inc.
VBI Vaccines Inc. (NasdaqCM:VBIV)
Life Sciences Tools and Services
VBI Vaccines Inc. (NasdaqCM:VBIV) 2022 Form 10-K
Business Description: Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. As of September 28, 2023, Syneos Health, Inc. was taken private.
*denotes proprietary relationship